A5068093646- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Phagocytosis and Immune Regulation
- Renal and related cancers
- Blood Pressure and Hypertension Studies
- Global Public Health Policies and Epidemiology
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Treatments and Studies
- Economic and Financial Impacts of Cancer
- Multiple and Secondary Primary Cancers
- Telomeres, Telomerase, and Senescence
- Global Cancer Incidence and Screening
- Advances in Oncology and Radiotherapy
- Ethics in Clinical Research
- Neuroblastoma Research and Treatments
- Nuclear Structure and Function
- Genetic factors in colorectal cancer
- Biomedical Ethics and Regulation
- Smoking Behavior and Cessation
- Health and Conflict Studies
- Cancer Mechanisms and Therapy
- Cancer, Stress, Anesthesia, and Immune Response
- Digestive system and related health
Dana-Farber Cancer Institute
2024-2025
Harvard University
2024-2025
Boston University
2025
Lebanese University
2021-2023
Background and Objectives: Hypertension (HTN) is a major health concern that leads to cardiovascular disease premature death. Assessing HTN knowledge, attitude, practice (KAP) crucial for controlling HTN. This study aimed determine KAP among hypertensive patients residing in Lebanon. Methods: cross-sectional involved 342 patients. A questionnaire form was used collect data related patients' characteristics. SPSS scores, descriptive statistics, correlations. Results: Data from analyzed of...
594 Background: Kidney injury molecule-1 (KIM-1) is a circulating biomarker for renal cell carcinoma. The JAVELIN Renal 101 trial established avelumab and axitinib as standard treatment regimen advanced carcinoma (aRCC). In this post-hoc analysis, we evaluated whether baseline plasma KIM-1 change on are associated with outcomes in 101. Methods: Patients aRCC were randomized to plus (Av/Ax) or sunitinib (Sun), previously described. was measured at (C1D1) C3D1 using Luminex microbead-based...
505 Background: The IMDC model has been effectively used to predict patients’ (pts) outcomes with mRCC, significantly guiding treatment decisions in the era of immune checkpoint inhibitors (ICIs) that have improved survival. In this study, we aim characterize clinical between patients classified as low (L, score 0) vs. low-intermediate (L/I, 1) categories. Methods: Data pts mRCC receiving first-line (1L) ICI-based therapies scores 0 or 1 was collected from IMDC. Pts were further subdivided...
509 Background: Comorbidities pose a challenge in the treatment of patients with cancer and present barrier to inclusion clinical trials. While effect comorbidities on efficacy immunotherapy (IO) has been studied various malignancies, it remains unclear metastatic renal cell carcinoma (mRCC) treated IO-based combinations. Methods: Data from mRCC receiving combinations (IO+IO or IO+anti-vascular endothelial growth factor (VEGF)) as first-line were collected Dana-Farber Cancer Institute Tom...
253 Background: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of that can arise after androgen blockade. Early detection NEPC has prognostic and therapeutic implications but remains challenging. (NE) transformation spatially heterogeneous, with co-existing NE adenocarcinoma (AD) components across a patient's disease burden, leading to underdiagnosis using tumor biopsy. Moreover, treatment response assessment cross-sectional imaging cannot distinguish changes in AD...
582 Background: Kidney injury molecule-1 (KIM-1) is overexpressed in clear cell and papillary renal carcinoma (RCC) proximal tubular kidney injury. While circulating KIM-1 a minimally invasive biomarker for RCC, it unknown whether disease, common comorbidity among RCC patients, impacts the association of with outcomes. We evaluated between outcomes metastatic after adjustment multiple biomarkers using plasma proteomics. Methods: Plasma samples from patients were obtained prior to 1 st line...
562 Background: ICI-based therapies are the cornerstone of treatment for advanced RCC. While many studies have focused on tumor-based biomarkers, circulating factors play an important role in therapeutic response. This study utilized a high dimensional proteomic platform to investigate plasma proteins from RCC patients undergoing identify potential biomarkers associated with outcomes. Methods: A total 43 samples (n = 40 clear cell; n 3 non-clear cell) were collected 33 patients, 16 paired...
506 Background: Neurofibromin-2 (NF2) is a tumor suppressor gene that encodes the scaffolding protein merlin and commonly mutated in rare RCC subtypes: unclassified (uRCC), papillary (pRCC), collecting duct carcinoma (CDCA), emerging entity, biphasic hyalinizing psammomatous (BHP-RCC). Merlin loss/deficiency by immunohistochemistry (IHC) was recently demonstrated as reliable surrogate marker of NF2 genomic alterations (GAs). We report first clinical outcomes patients (pts) with...
The Arab region comprises 22 countries located in the Middle East and North Africa, sharing cultural linguistic ties. have continued to lag terms of biomedical research compared other nations for several past decades. Cancer is a major public health concern, being second leading cause death globally. Given that high activity on cancer reflects positively screening programs, awareness, clinical practice, this article aimed examine trend world between 2005 2019.Between 2019, number...
Abstract Background Telomerase reverse transcriptase (TERT) gene promoter mutations have been explored, as biomarkers of improved survival for patients with cancer receiving immune checkpoint inhibitors. We sought to investigate their prevalence by race and sex across different types inform patient selection in clinical trials. Results In this observational study, 31 925 underwent next-generation sequencing tumors 88% (27 970) self-reported being Whites, 7.1% (2273) Asians, 5.3% (1682)...
Abstract Background c-Met, a receptor tyrosine kinase (RTK), is overexpressed in renal cell carcinoma (RCC) and correlates with decreased survival rate. Upon binding to its specific ligand, Hepatocyte Growth Factor (HGF), c-Met activates pro-tumorigenic signaling pathways. Cabozantinib (Cabo) inhibits few other RTKs, including AXL, approved for the treatment of patients advanced-stage RCC. AXL GAS6, are RCC also markers poor prognosis. The role potential crosstalk cancer need be thoroughly...
Abstract Purpose The Arab region comprises 22 countries located in the Middle East and North Africa, sharing cultural linguistic ties. have continued to lag terms of biomedical research compared other nations for several past decades. Cancer is a major public health concern, being second leading cause death globally. Given that high activity on cancer reflects positively onto screening programs, awareness, clinical practice, this article aimed examine trend world between 2005 2019. Methods...
e16529 Background: Immunotherapy (IO) has become a cornerstone in the standard of care patients (pts) with metastatic clear cell renal carcinoma (mccRCC). Recent studies suggest concomitant beta-blockers (BB) use may improve effectiveness IO melanoma by increasing CD8+ T cells tumor infiltration through β-adrenergic blockade. Herein, we assess impact BB on clinical outcomes pts mccRCC treated IO-based regimens first-line (1L) settings. Methods: Real-world data from Dana-Farber Cancer...
4515 Background: RCC is notable for a high CD8+ T cell infiltration despite its modest tumor mutational load. However, does not correlate with ICI response, highlighting the need to understand cellular composition and phenotype. We conducted comprehensive dissection of microenvironment (TME) using pre- post-ICI treatment samples identify specific T-cell populations associated efficacy in RCC. Methods: A total 70 (n = 59 clear cell; n 11 non-clear cell) from 63 patients were collected before...
9000 Background: Despite IMGs accounting for up to one-third of all practicing oncologists in the United States, little is known about their contributions presentations at international oncology meetings, such as American Society Clinical Oncology (ASCO). Therefore, we investigated representation invited faculty roles ASCO Annual Meetings. Methods: Speaker presentation details 2022 and 2023 Meetings were collected using publicly available program guides. We presentation-level variables...
4551 Background: Despite the improvements in genomic and pathological techniques to identify renal cell carcinoma (RCC), 2-6% of all patients with RCC cannot be classified into a particular subgroup, thus called “unclassified” (uRCC). Ascertaining profile those may help select proper treatment find novel targets. Methods: The American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database v15.0 was used by using OncoTree codes. All...
4543 Background: High expression of the receptor tyrosine kinase AXL has been associated with resistance to targeted agents and anti-PD-1 therapy in multiple tumor types, including metastatic clear cell Renal Cell Carcinoma (mccRCC). Cabozantinib (cabo), a multitargeted inhibitor (TKI) active against VEGFR, MET, AXL, is approved for treatment mccRCC, but no predictive biomarkers are available. Here, we analyzed samples from METEOR trial assess whether predicts improved clinical outcomes cabo...
Abstract Background Despite the improvements in genomic and pathological techniques to identify renal cell carcinoma (RCC), 2-6% of all patients with RCC cannot be classified into a particular subgroup, thus called “unclassified” (uRCC). Ascertaining profile those may help select proper treatment find novel targets. Methods The American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database v15.0 was used by using OncoTree codes. All...